Literature DB >> 35084696

Drug Treatment of Heart Failure in Children: Gaps and Opportunities.

Molly Weisert1,2, Jennifer A Su1,2, Jondavid Menteer1,2, Robert E Shaddy1,2, Paul F Kantor3,4.   

Abstract

Medical therapy for pediatric heart failure is based on a detailed mechanistic understanding of the underlying causes, which are diverse and unlike those encountered in most adult patients. Diuresis and improved perfusion are the immediate goals of care in the child with acute decompensated heart failure. Conversion to maintenance oral therapy for heart failure is based on the results of landmark studies in adults, as well as recent pediatric clinical trials and heart failure guidelines. There will continue to be an important role for newer drugs, some of which are in active trials in adults, and some of which are already approved for use in children. The need to plan for clinical trials in children during drug development for heart failure is emphasized.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh：

Year:  2022        PMID： 35084696     DOI： 10.1007/s40272-021-00485-9

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN： 1174-5878            Impact factor:   3.022


  99 in total

1.  Team management of patients with heart failure: A statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association.

Authors:  K L Grady; K Dracup; G Kennedy; D K Moser; M Piano; L W Stevenson; J B Young
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

Review 2.  Optimizing therapy for complex or refractory heart failure: a management algorithm.

Authors:  L W Stevenson; B M Massie; G S Francis
Journal:  Am Heart J       Date:  1998-06       Impact factor: 4.749

3.  2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Steven M Hollenberg; Lynne Warner Stevenson; Tariq Ahmad; Vaibhav J Amin; Biykem Bozkurt; Javed Butler; Leslie L Davis; Mark H Drazner; James N Kirkpatrick; Pamela N Peterson; Brent N Reed; Christopher L Roy; Alan B Storrow
Journal:  J Am Coll Cardiol       Date:  2019-09-13       Impact factor: 24.094

4.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Authors:  Marvin A Konstam; Mihai Gheorghiade; John C Burnett; Liliana Grinfeld; Aldo P Maggioni; Karl Swedberg; James E Udelson; Faiez Zannad; Thomas Cook; John Ouyang; Christopher Zimmer; Cesare Orlandi
Journal:  JAMA       Date:  2007-03-25       Impact factor: 56.272

5.  Survival With Continuous Outpatient Intravenous Inotrope Therapy in the Modern Era.

Authors:  Behram P Mody; Mohammed Hasan Khan; Syed Zaid; Chul Ahn; Amanda Lloji; Wilbert S Aronow; Chhaya A Gupta; Avi Levine; Alan L Gass; Howard A Cooper; Gregg M Lanier
Journal:  Am J Ther       Date:  2020-10-01       Impact factor: 2.688

6.  Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.

Authors:  Paul F Kantor; Jane Lougheed; Adrian Dancea; Michael McGillion; Nicole Barbosa; Carol Chan; Rejane Dillenburg; Joseph Atallah; Holger Buchholz; Catherine Chant-Gambacort; Jennifer Conway; Letizia Gardin; Kristen George; Steven Greenway; Derek G Human; Aamir Jeewa; Jack F Price; Robert D Ross; S Lucy Roche; Lindsay Ryerson; Reeni Soni; Judith Wilson; Kenny Wong
Journal:  Can J Cardiol       Date:  2013-12       Impact factor: 5.223

7.  Tolvaptan increases serum sodium in pediatric patients with heart failure.

Authors:  Rebecca B Regen; Ashley Gonzalez; Kasey Zawodniak; David Leonard; Raymond Quigley; Aliessa P Barnes; Joshua D Koch
Journal:  Pediatr Cardiol       Date:  2013-03-05       Impact factor: 1.655

8.  Tolvaptan add-on therapy in patients with acute heart failure: A systematic review and meta-analysis.

Authors:  Xiandu Luo; Qi Jin; Yanqing Wu
Journal:  Pharmacol Res Perspect       Date:  2020-06

Review 9.  Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials.

Authors:  Tariq Ahmad; P Elliott Miller; Megan McCullough; Nihar R Desai; Ralph Riello; Mitchell Psotka; Michael Böhm; Larry A Allen; John R Teerlink; Giuseppe M C Rosano; Joann Lindenfeld
Journal:  Eur J Heart Fail       Date:  2019-08-13       Impact factor: 15.534

10.  Haemodynamic profiles of children with end-stage heart failure.

Authors:  Sharon Chen; John C Dykes; Doff B McElhinney; Robert J Gajarski; Andrew Y Shin; Seth A Hollander; Melanie E Everitt; Jack F Price; Ravi R Thiagarajan; Steven J Kindel; Joseph W Rossano; Beth D Kaufman; Lindsay J May; Elizabeth Pruitt; David N Rosenthal; Christopher S Almond
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983
View more
  1 in total

1.  Can Pediatric Heart Failure Therapy Be Improved? Yes It Can, But….

Authors:  Dietmar Schranz
Journal:  Paediatr Drugs       Date:  2022-08-06       Impact factor: 3.930
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.